Development of Peptide-Based Cancer Theranostics

Peptides that covalently bind to protein targets offer a powerful strategy for the design of cancer theranostics by combining high molecular specificity with durable target engagement. Through incorporation of electrophilic warheads, these peptides can form irreversible bonds with nucleophilic residues on overexpressed or mutant cancer-associated proteins, enhancing binding affinity and residence time relative to noncovalent ligands. Conjugation of fluorophores or radioactive tracers can also illuminate tumours whilst retaining biological activity, allowing for these compounds to have dual functionality. We have a protein target of interest that we wish to explore in this drug design strategy for a number of paediatric cancers. Students interested in this project should have some experience in organic and/or peptide chemistry.